$14.84▼ 0.39 (2.56%)
Real-time prices · US MarketsRevenue expanding at 16% year-over-year.
currently unprofitable (-21% margin).
Quality
1.1
Health
7.4
Growth
7.7
Valuation
6.8
Sentiment
6
Analyst Target
$27.14
▲ +82.9% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
-16.2×
next 12 months est.
Market Cap
$1.7B
market capitalization
Div Yield
—
dividend yield
Profit Margin
-21.2%
net profit margin
Gross Margin
76.4%
revenue minus COGS
ROE
-43.2%
return on equity
Beta
0.94
vs S&P 500
52-Week Range
$10 — $21
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about NovoCure Limited right now?
NovoCure Limited's Q·Score is 5.6/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Revenue expanding at 16% year-over-year. Key area to monitor: currently unprofitable (-21% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for NVCR?
The consensus price target for NVCR is $27.14, based on ratings from 7 Wall Street analysts. This is 82.9% above the current price of $14.84. Price targets are forward-looking estimates and not guarantees of future performance.
Is NVCR overvalued or undervalued?
NovoCure Limited (NVCR) scores in line with sector averages on valuation metrics. The consensus analyst price target of $27.14 is 83% above the current price.
When does NovoCure Limited report its next earnings?
NovoCure Limited's next earnings report is expected on approximately October 29, 2026.
What is NovoCure Limited's profit margin?
NovoCure Limited has a net profit margin of -21.2%, indicating the company is currently operating at a net loss. Its gross margin stands at 76.4%, indicating a high-margin business model.
Is NovoCure Limited's revenue growing?
NovoCure Limited is reporting solid revenue growth of 15.6% year-over-year.
How much debt does NovoCure Limited have?
NovoCure Limited has a debt-to-equity ratio of 0.69×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 2.89×, indicating comfortable short-term liquidity.